OBSN Obseva

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019



Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in the Cantor Global Healthcare Conference taking place October 2-4, 2019 in New York City. ObsEva will present on Friday, October 4 at 7:45 a.m. Eastern time (ET).



The presentation webcast will be available in the “Investors” section of ObsEva’s website



About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit



For further information, please contact:



Media Contact Switzerland and Europe:

Christophe Lamps Dynamics Group



Office

7 Mobile





Media Contact U.S.:

Marion Janic RooneyPartners LLC



Office

Mobile



CEO Office Contact:

Shauna Dillon





Investor Contact:

Mario Corso

Senior Director, Investor Relations



Office

Mobile



##



Attachment

EN
27/09/2019

Underlying

OBSNObseva

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Obseva

 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from ...

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certai...

April 3, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Update on Board of Directors

ObsEva Announces Update on Board of Directors Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today. “We would like to warmly thank Catarina for her significant contribution to the company over the last years. We are grateful to have had the opportunity...

March 19, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will...

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack ...

February 28, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

Geneva Court Grants Temporary Moratorium to ObsEva

Geneva Court Grants Temporary Moratorium to ObsEva Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland. The Tribunal de première instance of Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner (commissaire) to supervise the company's activities durin...

January 31, 2024 1 EN
 PRESS RELEASE
Free
OBSN OBSEVA

ObsEva Announces Application for a Moratorium to Facilitate Pivotal De...

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland. The moratorium, if granted, will provide essential protection, enabling the company to focus on negotiations and...

November 30, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch